$NBY
NovaBay Pharmaceuticals, Inc. Stock $nby

$nby Overview Financials Valuation SEC Filings Company Website

2019 Q3 Form 10-Q Financial Statement

#000143774919021963 Filed on November 07, 2019

Income Statement

Concept	2019 Q3	2018 Q3	2018 Q2
Revenue	$1.615M	$3.142M	$2.794M
YoY Change	-48.6%	-23.2%	-32.22%
Cost Of Revenue	$401.0K	$332.0K	$479.0K
YoY Change	20.78%	-36.28%	-31.38%
Gross Profit	$1.214M	$2.810M	$2.315M
YoY Change	-56.8%	-21.29%	-32.39%
Gross Profit Margin	75.17%	89.43%	82.86%
Selling, General & Admin	$2.877M	$4.574M	$4.337M
YoY Change	-37.1%	-18.42%	-15.14%
% of Gross Profit	236.99%	162.78%	187.34%
Research & Development	$49.00K	$45.00K	$61.00K
YoY Change	8.89%	-65.91%	-12.86%
% of Gross Profit	4.04%	1.6%	2.63%
Depreciation & Amortization	$17.00K	$92.00K	$86.00K
YoY Change	-81.52%	411.11%	377.78%
% of Gross Profit	1.4%	3.27%	3.71%
Operating Expenses	$2.926M	$4.619M	$4.398M
YoY Change	-36.65%	-19.52%	-15.11%
Operating Profit	-$1.712M	-$1.809M	-$2.083M
YoY Change	-5.36%	-16.6%	18.55%
Interest Expense	$1.811M	$267.0K	$490.0K
YoY Change	578.28%	-195.36%	2350.0%
% of Operating Profit
Other Income/Expense, Net	-$719.0K	$4.000K	$5.000K
YoY Change	-18075.0%	33.33%	25.0%
Pretax Income	-$282.0K	-$1.538M	-$1.588M
YoY Change	-81.66%	-37.15%	-8.63%
Income Tax			$1.000K
% Of Pretax Income
Net Earnings	-$282.0K	-$1.538M	-$1.589M
YoY Change	-81.66%	-37.15%	-8.57%
Net Earnings / Revenue	-17.46%	-48.95%	-56.87%
Basic Earnings Per Share	-$0.01	-$0.09	-$0.09
Diluted Earnings Per Share	-$0.02	-$0.11	-$0.12
COMMON SHARES
Basic Shares Outstanding	23.10M	17.09M	17.09M
Diluted Shares Outstanding	23.21M	17.15M	17.29M

Balance Sheet

Concept	2019 Q3	2018 Q3	2018 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$9.020M	$5.207M	$6.830M
YoY Change	73.23%	-14.36%	19.41%
Cash & Equivalents	$9.020M	$5.207M	$6.833M
Short-Term Investments
Other Short-Term Assets	$279.0K	$234.0K	$215.0K
YoY Change	19.23%	24.47%	-21.53%
Inventory	$838.0K	$390.0K	$317.0K
Prepaid Expenses
Receivables	$1.505M	$2.612M	$2.020M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$12.50M	$9.528M	$10.77M
YoY Change	31.17%	-4.13%	-1.78%
LONG-TERM ASSETS
Property, Plant & Equipment	$128.0K	$271.0K	$351.0K
YoY Change	-52.77%	-44.92%	-24.03%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$542.0K	$566.0K	$582.0K
YoY Change	-4.24%	-9.58%	-9.2%
Total Long-Term Assets	$2.105M	$837.0K	$933.0K
YoY Change	151.49%	-25.13%	-15.41%
TOTAL ASSETS
Total Short-Term Assets	$12.50M	$9.528M	$10.77M
Total Long-Term Assets	$2.105M	$837.0K	$933.0K
Total Assets	$14.60M	$10.37M	$11.71M
YoY Change	40.89%	-6.25%	-3.02%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$503.0K	$564.0K	$329.0K
YoY Change	-10.82%	58.43%	-63.77%
Accrued Expenses	$1.642M	$2.751M	$2.665M
YoY Change	-40.31%	13.72%	61.03%
Deferred Revenue	$456.0K	$1.731M	$1.640M
YoY Change	-73.66%
Short-Term Debt	$3.045M	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$6.252M	$3.377M	$3.056M
YoY Change	85.13%	-35.82%	-35.46%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$315.0K	$198.0K	$198.0K
YoY Change	59.09%	-9.17%	-10.41%
Total Long-Term Liabilities	$315.0K	$198.0K	$198.0K
YoY Change	59.09%	-9.17%	-10.41%
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.252M	$3.377M	$3.056M
Total Long-Term Liabilities	$315.0K	$198.0K	$198.0K
Total Liabilities	$11.10M	$4.306M	$4.276M
YoY Change	157.69%	-53.32%	-51.74%
SHAREHOLDERS EQUITY
Retained Earnings	-$122.3M	-$113.7M	-$112.2M
YoY Change	7.58%	1.65%	2.52%
Common Stock	$252.0K	$171.0K	$171.0K
YoY Change	47.37%	11.04%	11.76%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$2.923M	$6.059M	$7.429M
YoY Change
Total Liabilities & Shareholders Equity	$14.60M	$10.37M	$11.71M
YoY Change	40.89%	-6.25%	-3.02%

Cashflow Statement

Concept	2019 Q3	2018 Q3	2018 Q2
OPERATING ACTIVITIES
Net Income	-$282.0K	-$1.538M	-$1.589M
YoY Change	-81.66%	-37.15%	-8.57%
Depreciation, Depletion And Amortization	$17.00K	$92.00K	$86.00K
YoY Change	-81.52%	411.11%	377.78%
Cash From Operating Activities	-$1.500M	-$1.615M	-$1.500M
YoY Change	-7.12%	-656.9%	-7.41%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	-$3.000K	-$10.00K
YoY Change	-100.0%	-95.71%	-90.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	$0.00	-$3.000K	-$10.00K
YoY Change	-100.0%	-95.71%	-90.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$4.200M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	6.852M	-3.000K	0.000
YoY Change	-228500.0%	-102.0%	-100.0%
NET CHANGE
Cash From Operating Activities	-1.500M	-1.615M	-1.500M
Cash From Investing Activities	0.000	-3.000K	-10.00K
Cash From Financing Activities	6.852M	-3.000K	0.000
Net Change In Cash	5.352M	-1.621M	-1.510M
YoY Change	-430.17%	-538.11%	-10.12%
FREE CASH FLOW
Cash From Operating Activities	-$1.500M	-$1.615M	-$1.500M
Capital Expenditures	$0.00	-$3.000K	-$10.00K
Free Cash Flow	-$1.500M	-$1.612M	-$1.490M
YoY Change	-6.95%	-547.78%	-1.97%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2019Q3	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
	nby	Addition Of Operating Lease Rightofuse Asset AdditionOfOperatingLeaseRightofuseAsset	2473000
	nby	Addition Of Operating Lease Rightofuse Asset AdditionOfOperatingLeaseRightofuseAsset
CY2019Q2	nby	Adjustments To Additional Paid In Capital Debt Discount Associated With Convertible Note Beneficial Conversion Feature AdjustmentsToAdditionalPaidInCapitalDebtDiscountAssociatedWithConvertibleNoteBeneficialConversionFeature	184000
CY2019Q2	nby	Adjustments To Additional Paid In Capital Stock Option Modification AdjustmentsToAdditionalPaidInCapitalStockOptionModification	21000
CY2019Q3	nby	Adjustments To Additional Paid In Capital Stock Option Modification AdjustmentsToAdditionalPaidInCapitalStockOptionModification	24000
CY2018Q1	nby	Adjustments To Additional Paid In Capital Stock Option Modification AdjustmentsToAdditionalPaidInCapitalStockOptionModification	77000
CY2019Q2	nby	Adjustments To Additional Paid In Capital Warrant Modification AdjustmentsToAdditionalPaidInCapitalWarrantModification
	nby	Allowance For Doubtful Accounts Past Due Period Threshold AllowanceForDoubtfulAccountsPastDuePeriodThreshold	P120D
	nby	Change In Accounts Payable And Accrued Liabilities For Property And Equipment Purchases ChangeInAccountsPayableAndAccruedLiabilitiesForPropertyAndEquipmentPurchases	10000
	nby	Change In Accounts Payable And Accrued Liabilities For Property And Equipment Purchases ChangeInAccountsPayableAndAccruedLiabilitiesForPropertyAndEquipmentPurchases	7000
CY2019Q2	nby	Class Of Warrant Or Right Exercised During Period ClassOfWarrantOrRightExercisedDuringPeriod	158400
CY2019Q3	nby	Class Of Warrant Or Right Exercised During Period ClassOfWarrantOrRightExercisedDuringPeriod	102602
	nby	Class Of Warrant Or Right Exercised During Period ClassOfWarrantOrRightExercisedDuringPeriod	394000
	nby	Class Of Warrant Or Right Exercised During Period Weighted Average Exercise Price ClassOfWarrantOrRightExercisedDuringPeriodWeightedAverageExercisePrice	0.21
	nby	Class Of Warrant Or Right Forfeited During Period ClassOfWarrantOrRightForfeitedDuringPeriod
	nby	Class Of Warrant Or Right Forfeited During Period Weighted Average Exercise Price ClassOfWarrantOrRightForfeitedDuringPeriodWeightedAverageExercisePrice
	nby	Class Of Warrant Or Right Issued During Period ClassOfWarrantOrRightIssuedDuringPeriod	8438000
	nby	Class Of Warrant Or Right Issued During Period Weighted Average Exercise Price ClassOfWarrantOrRightIssuedDuringPeriodWeightedAverageExercisePrice	1.11
CY2019Q3	nby	Contract With Customer Accrued Liabilities Current ContractWithCustomerAccruedLiabilitiesCurrent	983000
CY2018Q4	nby	Contract With Customer Accrued Liabilities Current ContractWithCustomerAccruedLiabilitiesCurrent	2282000
	nby	Contract With Customer Liability Current Additions ContractWithCustomerLiabilityCurrentAdditions	4982000
	nby	Contract With Customer Liability Current Deductions ContractWithCustomerLiabilityCurrentDeductions	5999000
CY2018Q4	nby	Contract With Customer Liability Deferred Revenue Current ContractWithCustomerLiabilityDeferredRevenueCurrent	41000
CY2019Q3	nby	Contract With Customer Liability Deferred Revenue Current ContractWithCustomerLiabilityDeferredRevenueCurrent
	nby	Contract With Customer Liability Deferred Revenue Current Additions ContractWithCustomerLiabilityDeferredRevenueCurrentAdditions
	nby	Contract With Customer Liability Deferred Revenue Current Deductions ContractWithCustomerLiabilityDeferredRevenueCurrentDeductions	41000
CY2018Q4	nby	Contract With Customer Liability Product Contracts Current ContractWithCustomerLiabilityProductContractsCurrent	1432000
CY2019Q3	nby	Contract With Customer Liability Product Contracts Current ContractWithCustomerLiabilityProductContractsCurrent	456000
	nby	Contract With Customer Liability Product Distribution Current Additions ContractWithCustomerLiabilityProductDistributionCurrentAdditions	4982000
	nby	Contract With Customer Liability Product Distribution Current Deductions ContractWithCustomerLiabilityProductDistributionCurrentDeductions	5958000
CY2018Q1	nby	Effect Of Adoption Of New Accounting Standard EffectOfAdoptionOfNewAccountingStandard	2638000
	nby	Fair Value Of Warrants Issued In Connection With Financings FairValueOfWarrantsIssuedInConnectionWithFinancings	5269000
	nby	Fair Value Of Warrants Issued In Connection With Financings FairValueOfWarrantsIssuedInConnectionWithFinancings
	nby	Increase Decrease In Deferred Rent IncreaseDecreaseInDeferredRent
	nby	Increase Decrease In Deferred Rent IncreaseDecreaseInDeferredRent	-48000
	nby	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-788000
	nby	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities
	nby	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	-679000
	nby	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets
	nby	Interest Expense Related To Amortization Of Debt Issuance Related To Related Party Notes Payable InterestExpenseRelatedToAmortizationOfDebtIssuanceRelatedToRelatedPartyNotesPayable	16000
	nby	Interest Expense Related To Amortization Of Debt Issuance Related To Related Party Notes Payable InterestExpenseRelatedToAmortizationOfDebtIssuanceRelatedToRelatedPartyNotesPayable
CY2019Q3	nby	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
CY2019Q3	nby	Lessor Operating Lease Payments To Be Received After Year Four LessorOperatingLeasePaymentsToBeReceivedAfterYearFour
CY2012Q1	nby	Minimum Common Stock Closing Bid Price Per Share MinimumCommonStockClosingBidPricePerShare	66.50
	nby	Number Of Major Distributors NumberOfMajorDistributors	3
	nby	Number Of Major Distributors NumberOfMajorDistributors	3
	nby	Number Of Major Source Manufacturers NumberOfMajorSourceManufacturers	2
	nby	Payment For Product Supply Period PaymentForProductSupplyPeriod	P30D
CY2019Q3	nby	Prepaid Due And Subscriptions PrepaidDueAndSubscriptions	42000
CY2018Q4	nby	Prepaid Due And Subscriptions PrepaidDueAndSubscriptions	130000
CY2019Q3	nby	Prepaid Employees Benefits PrepaidEmployeesBenefits	6000
CY2018Q4	nby	Prepaid Employees Benefits PrepaidEmployeesBenefits	113000
CY2019Q3	nby	Prepaid Sales Rebate PrepaidSalesRebate	550000
CY2018Q4	nby	Prepaid Sales Rebate PrepaidSalesRebate	925000
	nby	Proceeds From Preferred Stock Issuances Net ProceedsFromPreferredStockIssuancesNet	2598000
	nby	Proceeds From Preferred Stock Issuances Net ProceedsFromPreferredStockIssuancesNet
	nby	Proceeds From Sale Of Stock Options And Restricted Stock Sold To Cover Taxes ProceedsFromSaleOfStockOptionsAndRestrictedStockSoldToCoverTaxes	4000
	nby	Proceeds From Sale Of Stock Options And Restricted Stock Sold To Cover Taxes ProceedsFromSaleOfStockOptionsAndRestrictedStockSoldToCoverTaxes	1000
	nby	Proceeds From Stock Options And Restricted Stock Sold To Cover Taxes In Accounts Payable And Accrued Liabilities ProceedsFromStockOptionsAndRestrictedStockSoldToCoverTaxesInAccountsPayableAndAccruedLiabilities
	nby	Proceeds From Stock Options And Restricted Stock Sold To Cover Taxes In Accounts Payable And Accrued Liabilities ProceedsFromStockOptionsAndRestrictedStockSoldToCoverTaxesInAccountsPayableAndAccruedLiabilities	-1000
CY2019Q1	nby	Reclassification Of Warrant Liability To Equity ReclassificationOfWarrantLiabilityToEquity	56000
CY2019Q3	nby	Rent Receivable RentReceivable	83000
CY2018Q4	nby	Rent Receivable RentReceivable	108000
CY2019Q3	nby	Restricted Stock Units Issued Value Related To Employee Separation Agreement RestrictedStockUnitsIssuedValueRelatedToEmployeeSeparationAgreement	220000
CY2019Q3	nby	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options And Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	4.27
	nby	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options And Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm	P7Y146D
CY2019Q3	nby	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options And Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsVestedInPeriod	1769000
CY2019Q3	nby	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options And Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsVestedInPeriodWeightedAverageGrantDateFairValue	4.86
	nby	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options And Options Vested Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsVestedWeightedAverageRemainingContractualTerm	P7Y36D
CY2019Q3	nby	Share Based Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Exercisable Number ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsExercisableNumber	1769000
CY2019Q3	nby	Share Based Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsExercisableWeightedAverageExercisePrice	4.86
	nby	Share Based Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Exercisable Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsExercisableWeightedAverageRemainingContractualTerm	P7Y36D
CY2018Q4	nby	Share Based Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Outstanding ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsOutstanding	3374000
CY2019Q3	nby	Share Based Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Outstanding ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsOutstanding	2240000
CY2018Q4	nby	Share Based Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsOutstandingWeightedAverageExercisePrice	4.13
CY2019Q3	nby	Share Based Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsOutstandingWeightedAverageExercisePrice	4.24
CY2019Q3	nby	Share Based Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	40000
CY2019Q3	nby	Share Based Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsVestedAndExpectedToVestOutstandingNumber	2218000
	nby	Share Based Compensation Expense For Stock Option Modification ShareBasedCompensationExpenseForStockOptionModification	45000
	nby	Share Based Compensation Expense For Stock Option Modification ShareBasedCompensationExpenseForStockOptionModification	77000
CY2019Q2	nby	Stock Issued In Connection With Exercise Of Warrants Value StockIssuedInConnectionWithExerciseOfWarrantsValue	446000
CY2019Q3	nby	Stock Issued In Connection With Exercise Of Warrants Value StockIssuedInConnectionWithExerciseOfWarrantsValue	174000
CY2018Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3180000
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13528000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	343000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	508000
CY2019Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	24000
CY2019Q3	us-gaap	Accounts Notes And Loans Receivable Net Current AccountsNotesAndLoansReceivableNetCurrent	1505000
CY2018Q4	us-gaap	Accounts Notes And Loans Receivable Net Current AccountsNotesAndLoansReceivableNetCurrent	3385000
CY2019Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	503000
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	551000
CY2019Q3	us-gaap	Accounts Receivable Related Parties AccountsReceivableRelatedParties	145000
CY2018Q4	us-gaap	Accounts Receivable Related Parties AccountsReceivableRelatedParties	39000
CY2019Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1642000
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3255000
CY2019Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	559000
CY2018Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	509000
CY2019Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	125009000
CY2018Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	119764000
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	184000
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	107000
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	95000
CY2019Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	68000
CY2018Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	102000
CY2018Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	148000
CY2018Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	163000
CY2018Q1	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	393000
CY2018Q2	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	6000
CY2019Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	106000
CY2018Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	168000
CY2018Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	10000
CY2019Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	24000
CY2018Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	10000
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	498000
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts
CY2019Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13378000
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3180000
CY2019Q3	us-gaap	Assets Assets	14603000
CY2018Q4	us-gaap	Assets Assets	9361000
CY2019Q3	us-gaap	Assets Current AssetsCurrent	12498000
CY2018Q4	us-gaap	Assets Current AssetsCurrent	8608000
CY2019Q3	us-gaap	Common Stock Value CommonStockValue	252000
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	171000
CY2019Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9020000
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3183000
CY2019Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	9495000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3658000
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3673000
CY2018Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	5682000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	5837000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	2009000
CY2011Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	33.25
CY2018Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.81
CY2019Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.09
CY2019Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	334109
CY2018Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	544000
CY2019Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	8588000
CY2019Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2019Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	240000000
CY2019Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	25202000
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	17089000
CY2019Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	25202000
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	17089000
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Concentrations of Credit Risk and Major Partners</div></div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits of cash and cash equivalents with <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> highly-rated, major financial institution in the United States.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">  </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">Deposits in this bank <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>exceed the amount of federal insurance provided on such deposits. The Company does <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> believe it is exposed to significant credit risk due to the financial position of the financial institution in which the deposits are held.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">During the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">nine</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2019 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> revenues were derived primarily from sales of Avenova directly to doctors through the Company’s webstore, directly to consumers through Amazon.com, and to pharmacies via <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> major distribution partners.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">During the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">nine</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2019 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> revenues from our major distribution or collaboration partners greater than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10%</div> were as follows:</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 30pt;text-align:left;"> </div> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin-right: 2.5%; margin-left: 2.5%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Three Months Ended September 30,</div></div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Nine Months Ended September 30,</div></div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 48%; border-bottom: thin solid rgb(0, 0, 0);"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-weight: bold;">Major distribution or collaboration partner </div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2019</div></div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2019</div></div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Distributer A</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">%</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">25</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">%</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">17</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">%</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">22</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">%</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Distributer B</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">%</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">24</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">%</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">17</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">%</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">25</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">%</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Distributer C</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">19</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">%</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">25</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">%</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">%</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">25</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">%</div> </td> </tr> </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 30pt;text-align:center;"> </div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2019 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018, </div>accounts receivable from our major distribution or collaboration partners greater than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10%</div> were as follows:</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:35.75pt;margin-right:50.15pt;margin-top:0pt;text-align:left;"> </div> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin-right: 5%; margin-left: 5%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">September 30,</div></div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31,</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 66%; border-bottom: thin solid rgb(0, 0, 0);"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-weight: bold;">Major distribution or collaboration partner</div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2019</div></div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Distributer A</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">29</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">32</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Distributer B</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">20</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">23</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Distributer C</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.5pt;text-align:center;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">The Company relies on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">two</div> contract sole source manufacturers to produce its finished goods. The Company does <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> have any manufacturing facilities and intends to continue to rely on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div> parties for the supply of finished goods. There is a risk however that <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div> party manufacturers <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> be able to meet the Company’s needs with respect to timing, quantity or quality.</div></div></div></div></div>
CY2019Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	0
CY2018Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	41000
CY2018Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1473000
CY2019Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	456000
CY2019Q3	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	1890000
CY2018Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent
CY2019Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	401000
CY2018Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	332000
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1145000
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1062000
CY2019Q3	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent
CY2018Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	101000
CY2019Q3	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent
CY2018Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	184000
CY2019Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	17000
CY2018Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	92000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	50000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	219000
CY2019Q3	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	669000
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	423000
CY2018Q3	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet
CY2019Q3	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	4000
CY2018Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent
CY2019Q3	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	-75000
CY2018Q3	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	-267000
	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	-971000
CY2019Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2018Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.09
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.36
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.31
CY2019Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.02
CY2018Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.11
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.37
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.36
CY2019Q3	us-gaap	Embedded Derivative Fair Value Of Embedded Derivative Liability EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability	4000
	us-gaap	Embedded Derivative No Longer Bifurcated Amount Reclassified To Stockholders Equity EmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity	553000
	us-gaap	Embedded Derivative No Longer Bifurcated Amount Reclassified To Stockholders Equity EmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity
CY2019Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	552000
CY2018Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	708000
CY2019Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1480000
CY2018Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-267000
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-936000
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-971000
CY2019Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit
CY2018Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	178000
CY2019Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	606000
CY2019Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	939000
CY2019Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	3906000
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-32000
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-1000
CY2019Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1333000
CY2018Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1344000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4136000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4326000
CY2019Q3	us-gaap	Gross Profit GrossProfit	1214000
CY2018Q3	us-gaap	Gross Profit GrossProfit	2810000
	us-gaap	Gross Profit GrossProfit	3750000
	us-gaap	Gross Profit GrossProfit	7821000
CY2018Q3	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2019Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-282000
CY2018Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1538000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-6969000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5276000
CY2018Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1000
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1551000
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-56000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1880000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1546000
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-41000
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-13000
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	558000
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-89000
	us-gaap	Increase Decrease In Notes Payable Related Parties Current IncreaseDecreaseInNotesPayableRelatedPartiesCurrent	159000
	us-gaap	Increase Decrease In Notes Payable Related Parties Current IncreaseDecreaseInNotesPayableRelatedPartiesCurrent
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-10000
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-48000
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	117000
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-573000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-379000
CY2019Q3	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	117000
CY2018Q3	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	59000
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	192000
CY2019Q3	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	1000
	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	16000
CY2019Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	797000
CY2018Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	167000
CY2019Q3	us-gaap	Inventory Net InventoryNet	838000
CY2018Q4	us-gaap	Inventory Net InventoryNet	280000
CY2019Q3	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	176000
CY2018Q4	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	217000
CY2019Q3	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	135000
CY2018Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	104000
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	59000
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims
CY2019Q3	us-gaap	Lease Cost LeaseCost	115000
	us-gaap	Lease Cost LeaseCost	387000
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1881000
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	323000
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	75000
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	438000
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1045000
CY2019Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	196000
CY2019Q3	us-gaap	Lessor Operating Lease Payments To Be Received LessorOperatingLeasePaymentsToBeReceived	769000
CY2019Q3	us-gaap	Lessor Operating Lease Payments To Be Received Four Years LessorOperatingLeasePaymentsToBeReceivedFourYears
CY2019Q3	us-gaap	Lessor Operating Lease Payments To Be Received Next Twelve Months LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths	192000
CY2019Q3	us-gaap	Lessor Operating Lease Payments To Be Received Three Years LessorOperatingLeasePaymentsToBeReceivedThreeYears
CY2019Q3	us-gaap	Lessor Operating Lease Payments To Be Received Two Years LessorOperatingLeasePaymentsToBeReceivedTwoYears	577000
CY2019Q3	us-gaap	Liabilities Liabilities	11096000
CY2018Q4	us-gaap	Liabilities Liabilities	4407000
CY2019Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	14603000
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	9361000
CY2019Q3	us-gaap	Liabilities Current LiabilitiesCurrent	6252000
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3847000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	12356000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5597000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-19000
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-1538000
	us-gaap	Net Income Loss NetIncomeLoss	-6972000
	us-gaap	Net Income Loss NetIncomeLoss	-5277000
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-4189000
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-2501000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-13000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6500000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3575000
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-282000
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-2150000
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	-1589000
CY2019Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-282000
CY2018Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1538000
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-7001000
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5277000
CY2019Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-357000
CY2018Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-1805000
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-7001000
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-6248000
CY2011Q3	us-gaap	Noncash Or Part Noncash Acquisition Noncash Financial Or Equity Instrument Consideration Warrants Issued1 NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued1	139520
CY2019Q3	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	1155000
CY2018Q4	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	4
CY2019Q3	us-gaap	Operating Expenses OperatingExpenses	2926000
CY2018Q3	us-gaap	Operating Expenses OperatingExpenses	4619000
	us-gaap	Operating Expenses OperatingExpenses	10912000
	us-gaap	Operating Expenses OperatingExpenses	14081000
CY2019Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1712000
CY2018Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1809000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-7162000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-6260000
CY2019Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	273000
	us-gaap	Operating Lease Cost OperatingLeaseCost	861000
CY2019Q1	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	125000
	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	125000
	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss
CY2019Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	1685000
CY2019Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1058000
CY2018Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent
CY2019Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	627000
CY2018Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent
CY2019Q3	us-gaap	Operating Lease Payments OperatingLeasePayments	322000
	us-gaap	Operating Lease Payments OperatingLeasePayments	970000
CY2019Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1435000
CY2018Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset
CY2019Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.12
CY2019Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y292D
CY2019Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	107000
CY2018Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	164000
CY2019Q3	us-gaap	Other Assets Current OtherAssetsCurrent	279000
CY2018Q4	us-gaap	Other Assets Current OtherAssetsCurrent	297000
CY2019Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	542000
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	552000
CY2019Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	315000
CY2018Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	198000
CY2019Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-719000
CY2018Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	4000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1166000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	13000
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	202000
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts
	us-gaap	Payments Of Dividends PaymentsOfDividends	0
CY2019Q3	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	488000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	19000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	13000
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2019Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1135000
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1760000
CY2019Q3	us-gaap	Prepaid Insurance PrepaidInsurance	175000
CY2018Q4	us-gaap	Prepaid Insurance PrepaidInsurance	57000
CY2019Q3	us-gaap	Prepaid Rent PrepaidRent
CY2018Q4	us-gaap	Prepaid Rent PrepaidRent	130000
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	2000000
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt
CY2019Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	4200000
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	6700000
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	5585000
CY2019Q3	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	2700000
	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	1000000
	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	189000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	11000
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	67000
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises
CY2019Q3	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	475000
CY2019Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	687000
CY2018Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	710000
CY2019Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	128000
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	201000
CY2019Q3	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	162000
CY2018Q3	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	0
	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	376000
	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	359000
CY2019Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	49000
CY2018Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	45000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	166000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	152000
CY2018Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	475000
	us-gaap	Restricted Stock Expense RestrictedStockExpense	228000
	us-gaap	Restricted Stock Expense RestrictedStockExpense
CY2019Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-122338000
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-114981000
CY2019Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	1615000
CY2018Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	3142000
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	4895000
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	8883000
CY2019Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1544000
CY2018Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	3230000
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	6610000
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	9603000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	1185000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	3.62
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	140000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	819000
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	8000
CY2019Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	40000
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.30
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.36
CY2019Q1	us-gaap	Share Based Goods And Nonemployee Services Transaction Stockholders Equity ShareBasedGoodsAndNonemployeeServicesTransactionStockholdersEquity	7000
CY2019Q2	us-gaap	Share Based Goods And Nonemployee Services Transaction Stockholders Equity ShareBasedGoodsAndNonemployeeServicesTransactionStockholdersEquity	7000
CY2019Q3	us-gaap	Share Based Goods And Nonemployee Services Transaction Stockholders Equity ShareBasedGoodsAndNonemployeeServicesTransactionStockholdersEquity	14000
CY2018Q1	us-gaap	Share Based Goods And Nonemployee Services Transaction Stockholders Equity ShareBasedGoodsAndNonemployeeServicesTransactionStockholdersEquity	7000
CY2018Q2	us-gaap	Share Based Goods And Nonemployee Services Transaction Stockholders Equity ShareBasedGoodsAndNonemployeeServicesTransactionStockholdersEquity	6000
CY2018Q3	us-gaap	Share Based Goods And Nonemployee Services Transaction Stockholders Equity ShareBasedGoodsAndNonemployeeServicesTransactionStockholdersEquity	5000
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y73D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y146D
CY2019Q3	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	1
CY2015Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	5
CY2019Q3	us-gaap	Stock And Warrants Issued During Period Value Preferred Stock And Warrants StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
CY2019Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	4198566
CY2019Q3	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	3902000
CY2018Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	178000
CY2019Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	23213000
CY2018Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	17148000
CY2019Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1036000
CY2018Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	5984000
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	1669000
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	2594000
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	8870000
CY2018Q2	us-gaap	Stockholders Equity StockholdersEquity	7429000
CY2019Q3	us-gaap	Warrant Down Round Feature Increase Decrease In Equity Amount WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount
CY2018Q3	us-gaap	Warrant Down Round Feature Increase Decrease In Equity Amount WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount
	us-gaap	Warrant Down Round Feature Increase Decrease In Equity Amount WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount	29000
	us-gaap	Warrant Down Round Feature Increase Decrease In Equity Amount WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount
CY2018Q3	us-gaap	Stockholders Equity StockholdersEquity	6059000
CY2019Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2467000
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	83000
CY2018Q3	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	4000
CY2019Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	189000
CY2018Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	11000
CY2019Q3	us-gaap	Stockholders Equity StockholdersEquity	2923000
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	4954000
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	1129000
CY2019Q3	us-gaap	Sublease Income SubleaseIncome	158000
	us-gaap	Sublease Income SubleaseIncome	474000
CY2019Q3	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	584000
CY2018Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent
CY2019Q3	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.01
CY2018Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.01
CY2019Q3	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	2700000
CY2018Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	2700000
CY2019Q3	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	2700000
CY2018Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	0
CY2019Q3	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	2700000
CY2018Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0
	us-gaap	Use Of Estimates UseOfEstimates	<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Use of Estimates </div></div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. These estimates include useful lives for property and equipment and related depreciation calculations, estimated amortization periods for payments received from product development and license agreements as they relate to revenue recognition, assumptions for valuing options and warrants, and income taxes. Actual results could differ from those estimates.</div></div></div></div></div>
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	19623000
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	17056000
CY2019Q3	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	23096000
CY2018Q3	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	17089000
	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	19623000
	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	16864000
CY2019Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	23096000
CY2018Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	17089000
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	19623000
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	16864000

Files In Submission

Name	View Source	Status
0001437749-19-021963-index-headers.html	Edgar Link	pending
0001437749-19-021963-index.html	Edgar Link	pending
0001437749-19-021963.txt	Edgar Link	pending
0001437749-19-021963-xbrl.zip	Edgar Link	pending
ex_162815.htm	Edgar Link	pending
ex_162816.htm	Edgar Link	pending
ex_162817.htm	Edgar Link	pending
ex_162818.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
nby-20190930.xml	Edgar Link	completed
nby-20190930.xsd	Edgar Link	pending
nby-20190930_cal.xml	Edgar Link	unprocessable
nby-20190930_def.xml	Edgar Link	unprocessable
nby-20190930_lab.xml	Edgar Link	unprocessable
nby-20190930_pre.xml	Edgar Link	unprocessable
nby20190930_10q.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NBY
NovaBay Pharmaceuticals, Inc. Stock $nby

2019 Q3 Form 10-Q Financial Statement

#000143774919021963 Filed on November 07, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NBY NovaBay Pharmaceuticals, Inc. Stock $nby

2019 Q3 Form 10-Q Financial Statement

#000143774919021963 Filed on November 07, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NBY
NovaBay Pharmaceuticals, Inc. Stock $nby